MicroPort NeuroTech Limited (2172) AI Stock Analysis

• Market Cap: HK$6.93B
• Dividend Yield: 1.35%
• Average Volume (3M): 3.35M
• Price to Earnings (P/E): 31.3
• Beta (1Y): 0.99
• Revenue Growth: -5.18%
• EPS Growth: -9.69%
• Country: HK
• Employees: 527
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.17
• Shares Outstanding: 585,034,800
• 10 Day Avg. Volume: 2,487,263
• 30 Day Avg. Volume: 3,346,060
• PEG Ratio: 0.24
• Price to Book (P/B): 2.74
• Price to Sales (P/S): 6.15
• P/FCF Ratio: 16.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: HK$12.00 ▲(6.67% Upside)

MicroPort NeuroTech Limited's overall stock score is primarily influenced by its strong financial performance, despite concerns about cash flow. The technical analysis indicates bearish momentum, and the valuation suggests potential overvaluation. The absence of earnings call data and corporate events means these factors do not impact the score.

MicroPort NeuroTech Limited Business Overview & Revenue Model

Company Description

MicroPort NeuroTech Limited (2172) is a medical technology company specializing in the development, manufacturing, and marketing of innovative neurovascular devices. The company operates within the healthcare sector, focusing on providing advanced solutions for the treatment of neurovascular diseases, including aneurysms and strokes. Its core products encompass a range of minimally invasive medical devices designed to improve patient outcomes and enhance the capabilities of healthcare providers in the neurovascular field.

How the Company Makes Money

MicroPort NeuroTech Limited makes money through the sale of its neurovascular devices to hospitals, clinics, and other healthcare providers. The company's revenue model is primarily based on the direct sale of its medical devices, which are used in various neurovascular procedures. Key revenue streams include the sales of embolization coils, stents, and flow diverters, which are integral to treating complex neurovascular conditions. Additionally, the company may engage in strategic partnerships with healthcare institutions and distributors to expand its market reach and enhance product accessibility, thus contributing to its earnings.

MicroPort NeuroTech Limited Financial Statement Overview

Summary

MicroPort NeuroTech Limited demonstrates strong revenue and profit growth, with a solid balance sheet indicating low leverage and efficient equity utilization. However, concerns about recent operational cash flow and cash generation capabilities highlight the need for improvement in cash flow operations to ensure sustained growth and liquidity.

Income Statement

MicroPort NeuroTech Limited has demonstrated robust revenue growth, with a notable increase from 2023 to 2024. The gross profit margin and net profit margin are strong, reflecting effective cost management and profitability. EBIT and EBITDA margins are also healthy, indicating operational efficiency and profitability. Overall, the income statement showcases a positive growth trajectory and solid profitability.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, signifying low leverage and financial stability. The return on equity is impressive, suggesting efficient use of equity to generate profits. However, the equity ratio indicates a high reliance on equity, which could limit leverage benefits. Overall, the balance sheet reflects financial strength with controlled liabilities.

Cash Flow

The cash flow statement reveals some concerns with operational cash flow being zero in the latest period, which could indicate cash generation issues. The free cash flow has fluctuated in previous years, but there is a lack of data for current growth assessment. Despite past positive free cash flow, the current lack of free cash flow data poses a risk to cash flow stability. The overall cash flow position needs improvement to ensure ongoing liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	736.47M	761.76M	665.62M	547.35M	382.80M	221.92M
Gross Profit	541.92M	555.93M	511.79M	393.00M	298.35M	164.78M
EBITDA	295.56M	340.48M	221.60M	175.46M	108.83M	68.24M
Net Income	203.58M	254.16M	145.55M	-21.77M	24.17M	45.29M
Balance Sheet
Total Assets	2.08B	2.04B	1.96B	1.82B	1.34B	785.61M
Cash, Cash Equivalents and Short-Term Investments	1.01B	1.06B	1.00B	1.13B	593.29M	440.40M
Total Debt	24.72M	37.12M	61.36M	85.24M	109.70M	331.15M
Total Liabilities	352.39M	335.70M	322.39M	331.35M	1.52B	412.73M
Stockholders Equity	1.73B	1.71B	1.64B	1.47B	-174.94M	372.88M
Cash Flow
Free Cash Flow	178.02M	275.54M	-48.83M	175.85M	99.43M	13.09M
Operating Cash Flow	183.06M	284.41M	153.78M	223.80M	157.41M	47.23M
Investing Cash Flow	-73.53M	-160.55M	-233.16M	-344.52M	-186.79M	-73.04M
Financing Cash Flow	-229.48M	-226.25M	-33.28M	329.54M	200.75M	431.88M

MicroPort NeuroTech Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2172, the sentiment is Neutral. The current price of 11.25 is below the 20-day moving average (MA) of 11.97, below the 50-day MA of 12.87, and below the 200-day MA of 11.84, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 44.84 is Neutral, neither overbought nor oversold. The STOCH value of 67.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2172.

MicroPort NeuroTech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1302	―	HK$8.68B	112.92	1.98%	―	3.42%	-70.82%
1858	―	HK$9.75B	36.61	5.55%	0.77%	-12.57%	-30.70%
2190	―	HK$7.81B	46.11	4.99%	0.46%	35.01%	483.73%
2172	―	HK$6.93B	31.33	11.79%	1.35%	-5.18%	-9.69%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	―	HK$2.99B	563.64	0.22%	―	-4.38%	―
9996	―	€3.93B	-16.01	-11.20%	―	29.25%	9.02%

MicroPort NeuroTech Limited Corporate Events

MicroPort NeuroScientific Grants Share Options to Employees

MicroPort NeuroScientific Corporation announced the granting of 402,300 share options to 63 employees as part of its Share Scheme. This initiative aims to incentivize employees by giving them a personal stake in the company, thereby promoting business development and success. The options have a ten-year validity and will vest over five years without additional performance targets, although they are subject to a clawback mechanism.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroTech Reports Strong Overseas Growth Amidst Revenue Challenges

MicroPort NeuroTech Limited announced its unaudited interim results for the first half of 2025, reporting a revenue of approximately RMB382.9 million. The company experienced a significant 67.4% increase in overseas business revenue compared to the previous year, driven by strong sales across various regions. However, the revenue from flow-diverting stents decreased due to volume-based procurements, and cerebral atherosclerotic stenosis products were impacted by the termination of previous distribution agreements. Despite these challenges, the company achieved a net profit of RMB92.7 million and declared an interim dividend of HK$0.05 per share.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroScientific Declares Interim Dividend for 2025

MicroPort NeuroScientific Corporation has announced an interim dividend of HKD 0.05 per share for the six months ending June 30, 2025. This announcement reflects the company’s commitment to returning value to its shareholders and may positively impact investor sentiment, reinforcing its stable financial performance and strategic growth in the neuro-intervention sector.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroScientific Schedules Board Meeting for Interim Results Review

MicroPort NeuroScientific Corporation has announced that its board of directors will meet on August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters, which could impact the company’s financial strategy and shareholder returns.